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Genetic Studies on Lung Tumor
Susceptibility and Histogenesis in Mice
by Alvin M. Malkinson*
The probability that a mouse develops a pulmonary tumor, as well as the structure of that tumor, are
dependent on several genes. Three pulmonary adenoma susceptibility (pas) genes predispose some inbred
strains todeveloplungtumors, even inthe absence ofcarcinogen exposure, and causeotherstoberesistant.
One pas gene is K-ras, which may also be overexpressed in these tumors in a mutated form capable of
transforming cells. Mice with activated Ha-ras transgenes override the resistant pas alleles and are born
with lung cancer. Susceptible strains have a higher turnover rate ofalveolar type II and bronchiolar Clara
cells, those cells from which lung tumors arise, than more resistant strains. A high precursor cell turnover
rate correlates with a propensity to neoplasia in other animal models as well, possibly due to low con-
centrations ofendogenous growthregulatory molecules such ascorticosterone andproteinkinaseC (PKC).
Neoplastic lung epithelial cells are relatively resistant to glucocorticoids and have low PKC levels. A set
of genes other than the pas genes governs the response to tumor modulation by butylated hydroxytoluene
(BHT). The genes that determine whether lung tumor multiplicity is enhanced by chronic BHT exposure
may regulate the ability to hydroxylate BHT at a tert-butyl position to form BHT-OH, a metabolite with
greater tumor-promoting potency than BHT. Inbred and recombinant inbred strain variations in adenoma
growth patterns indicate that another set of genes, which we have designatedpah for pulmonary adenoma
histogenesis, may determine which cell type becomes neoplastic and whether adenomas will undergo
malignant conversion.
Introduction
A major anticipation in developing genetically homo-
zygous strains of mice in the early part of this century
was that inbred strains derived by nonselective,
brother-sister mating schedules would have differing
proclivities toward pathological states, including cancer
(1). The hope that this would permit genetic dissection
ofthe mechanisms underlying cancer causation was im-
mediately realized when the first inbred strain, strain
A, was found to have a very high incidence of sponta-
neous lung tumors in contrast to randomly bred popu-
lations of wild mice. Following the demonstration that
distal application of a carcinogen could induce lung tu-
mors (2), Andervont (3) and Heston (4) showed that the
same set of genes governed whether an inbred strain
developed lung tumors spontaneously or in response to
a carcinogen. Sensitive A-strain mice did both, while
resistant C57BL/6J (hereafter B6) mice did neither. Be-
cause chemically induced lungtumors develop in atime-
dependent progression from hyperplasia to a benign
stage to malignancy, interactions between genetic fac-
tors and environmental agents that affect the initiation,
promotion, and progressionphases oftumorigenesis can
be studiedindependently. Identification ofthe celltypes
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from which lung tumors arise has stimulated the use of
established cell lines and procedures forisolating highly
enriched cell populations for in vitro studies. Two re-
views on genes that influence most lung tumor devel-
opment have recently appeared (5,6).
Multiple Pulmonary Adenoma
Susceptibility (pas) Genes
A strain A/J mouse that has not been exposed to any
known carcinogenic agent will have a few tumors at
autopsy; the lungs of an untreated B6 mouse will not.
If mice of both strains are treated with a carcinogen,
such as 1 mg/gbodyweight ofurethan, atanytime from
gestation into senescence, the tumor multiplicity in A/
J mice will be greatly amplified, while that of B6 mice
will remain close to zero. All ofthese tumors are visible
on the pleural surfaces of fixed lungs (7). If fresh, un-
fixed lungs are used to determine tumor multiplicity in
order to obtain tumor material suitable for subsequent
molecularandbiochemical studies, upto20% ofthetotal
numberoftumorsmaybepartially orcompletelyburied
within the lung and detectable only upon dissection.
Typically with this dose, an A/J lung will have
- 30
tumors when examined 14 to 16 weeks after urethan
administration, and a B6 lung < 1.0. Nineteen inbred
strains so treated (Table 1) can be classified into sen-A. M. MALKINSON
Table 1. Lung tumor incidence and multiplicity among inbred
strains 14 to 16 weeks after a single 1-mg urethan/g body weight
injection.a
Multiplicity, No.
Strains Incidence, % no. tumors/mouse strains
Sensitive 100 10-30 5
A, NGP, GR,
SWR, 020
Intermediate 60-90 1-9 8
MA, ST, BALB, 129,
PL, RIII, LP,
CBA
Resistant < 60 < 1 6
C57, SM, DBA, C3H,
SJL, AKR
aModified from Malkinson (5).
sitive, intermediate, and resistant categories based on
lung tumor incidence and multiplicity. The existence of
intermediate phenotypes indicates that susceptibility is
a multigene phenomenon. F2 and backcross data ob-
tainedincrossesusingA/Heand C57Lstrainsconfirmed
that more than a single gene determined lung tumor
multiplicity (4). Different susceptibility alleles generate
a continuum from the most sensitive (A/J, 100% inci-
dence, 30 tumors/mouse) to the most resistant (AKR/J
or AKR/N, 1 mouse out of25 had 1 tumor, the rest had
none).
The genetic nature of susceptibility differences has
been analyzed further using recombinant inbred (RI)
strains ofmice. RI strains are generated byfixingthose
random recombinational events that occur during a
cross between F1 hybrids by inbreeding (8). If the RI
strains all have identical phenotypes to one ofthe pro-
genitors from which they are derived, then the phen-
otype examined (e.g., lung tumor susceptibility) may
be determined by a single genetic locus. An RI strain
phenotype different from that of either progenitor can
only arise ifmore than one gene determined that trait.
Studieswiththe AXB and BXA RI strains derived from
A/J and B6 progenitors (described in more detail in the
next section) clearly demonstrate both parental and in-
termediate lung tumor multiplicities (9). Chi-square
analysis was most consistent with a model where three
genes, called pulmonary adenoma susceptibility, orpas
genes, determine susceptibility (10). Nonprogenitor
phenotypes indicative of more than a single suscepti-
bilitygene were alsoobservedwhentheCXB RI strains
derived from BALB/cBy and B6 mice (11) and the
SWXL RI strains derived from SWR/J and C57L/J (5)
were tested.
When F1 hybrids, which had beenformed by crossing
sensitive strain A (either the He or J substrain) with
resistant mice (B6, DBA, C3H, AKR, SJL, or NZB)
were treated with urethan, the subsequent tumor mul-
tiplicities were almost arithmetic means of the respec-
tive parental phenotypes (4,12; A.M. Malkinson, un-
published data). Intermediate multiplicities also were
observed when A/J was crossed with either of two in-
termediate strains, MA/My J and 129/J (A.M. Malkin-
son, unpublished data). Some exceptions to these ex-
amples of co-dominance have been reported, however.
In studies with the A/Fa and C57BL/6Fa substrains,
the sensitive phenotype appeared to be dominant (13).
A/J crossed with intermediate BALB/cByJ (12), with
resistant SM/J (A.M. Malkinson, unpublished data), or
with various resistant strains ofJapanese wild mice (K.
Moriwaki, personal communication) yielded F1 hybrids
in which the more resistant phenotype was observed.
Whetherthese results imply the existence ofa separate
class ofsuppressor genes or not is under investigation.
Roles of the ras Gene Family
A great advantage of establishing the tumor multi-
plicities among the AXB and BXA RI strains is that
this strain distribution pattern can be compared with
that of any trait for which A/J and B6 mice differ. Be-
cause 46 AXB and BXA RI strains have been estab-
lished (14), a good correlation between SDPs is highly
improbable unless the traits are indeed related to each
other.
Inbred mouse strains display an RFLP (restriction-
fragment-length polymorphism) of the K-ras proto-on-
cogene in response to Eco RI-catalyzed digestion near
the first exon (15). Whether a strain had a 0.55 or 0.70
kb fragment correlated with their sensitivity or resist-
ance to lung tumor development, respectively. Two
strains included in the RFLP analysis whose suscepti-
bility was unknown at the time ofpublication were sub-
sequently found to conform to this 0.55/sensitive, 0.70/
resistant pattern (5). Ryan et al. (15) determined the
SDP for the K-ras RFLP amongthe AXB and BXA RI
strains and compared that to the previously established
SDP for tumor multiplicities. The excellent association
that they found is even better now that we have ana-
lyzed yet more lungtumormultiplicities inthese strains
(Fig. 1). Although the trend is unambiguous, strains
with the same K-ras RFLP can have dissimilar multi-
plicities. This confirms the existence ofotherpas genes
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FIGURE 1. Lung adenoma multiplicities in AXB and BXA strains 4
months following a single treatment with 1 mg urethan/g body
weight. Themultiplicities, arrangedindecreasingorder, aretaken
fromMalkinson etal. (9)asslightlymodifiedbyrecentunpublished
studies. The K-ras RFLPs of these strains, taken from Ryan et
al. (15), are indicated as (0), 0.55 kb or (0), 0.70 kb.
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that influence tumor multiplicity, even if the ultimate
function of these genes is to affect expression or the
mutability of K-ras.
Anderson and colleagues tested the DNA of mouse
lung tumors for transforming activity and found that
this resulted from K-ras oncogenes mutated at codons
12 or 61, depending on the carcinogen used to induce
the tumors (16). Spontaneous tumors had K-ras muta-
tions at these sites as well. This mutated K-ras is some-
times overexpressed in lung tumors and in neoplastic
cell lines established from tumors or as spontaneous
transformants in culture when compared to normal lung
or nontumorigenic lung epithelial cell lines (D.G. Beer
and A.M. Malkinson, unpublished data). The impor-
tance of ras genes in regulating mouse lung tumorige-
nesis is also shown by studies with transgenic mice.
Activated Ha-ras transgenes attached to various pro-
moter regions (e.g., albumin, SV40T, MMTV) induced
spontaneous lung cancer at very high frequencies (17-
19). The host strains used in these studies, (B6 x SJL)
F1 hybrids (17), (B6 x CD-1) F1 hybrids (18), and
BALB/cJ (19), had genetic backgrounds that were re-
sistant or of low intermediate susceptibility. Thus,
expression ofmutant ras genes apparently override re-
sistant pas alleles. It is of great interest that human
lung adenocarcinomas analogous to mouse lung tumors
with respect to histogenesis and genetic predisposition
(20,21) also have activated K-ras as their predominant
activated oncogene; other histological types of human
lung cancer have other kinds of activated oncogenes
(22).
Genes That Regulate Precursor Cell
Turnover
In several tissues, including colon (23), mammary
gland (24), liver (25), and skin (26), the likelihood that
cancer will ensue increases as the proliferative rate of
the cell type from which those tumors arise increases.
While proliferative rate, generally based on the thy-
midinelabelingindex (LI), istheassayedcharacteristic,
obviously, the cell turnover rate (both cell division and
cell death) is being assessed. In colon (23), the unsti-
mulated basal proliferative rates in cancer-prone ani-
mals arehigherthanincancer-resistant strains. Studies
with mammary gland (24), liver (25), and skin (26) dem-
onstrate that experimentally provoked enhancement of
cell division by noncarcinogenic stimuli heightens the
probability of subsequent neoplastic conversion. The
consequences of carcinogen treatment on cell kinetics
also may vary between sensitive and resistant strains.
All of these phenomena have been observed in mouse
lung.
The thymidine Lls of alveolar type II cells in un-
treated adult strains of mice correlated with their rel-
ative tumor susceptibilities (Table 2). We also analyzed
lung epithelial cell proliferation by applying prolifer-
ating cell nuclear antigen (PCNA) immunostaining to
tissue sections (28). PCNA is the accessory protein of
Table 2. Alveolar type II and bronchiolar Clara cell
proliferation in A/J and C57BL/6J mice.a
Thymidine LIb PCNA immunostainingc
Strains type II cells Alveolar Bronchiolar
A/J 15.2 ± 1.3d 23.1 + 1.4 37.7 ± 1.5
C57BL/6J 9.4 ± 1.8e 8.1 0 o.7c 21.9 ± 3.8*
aModified from Thaete et al. (27,28).
bLabeled cells/3000 cells; an estimate of cells in S phase.
CPCNA, proliferating cell nuclear antigen. Labeled nuclei/100 cells;
an estimate of cells in the late G,/S/early G2 stages.
dMeans ± SEM.
*p < 0.05 as compared to A/J mice.
DNA polymerase 8 (29), which is present in both the
late G1 and early G2 phases of the cell cycle as well as
S phase. A larger portion of an asynchronously prolif-
erating pool of cells can therefore be identified by this
antibody than is possible by using thymidine incorpo-
ration as a marker. PCNA immunostaining demon-
strated that both type II and bronchiolar nonciliated
Clara cells of A/J mice divided at a faster rate than in
B6 mice (Table 2). Thus, both precursor cell types for
lung adenomas [see "Pulmonary Adenoma Histogenesis
(pah) Genes"] turned over more rapidly in the lungs of
a sensitive strain than in a resistant one. Whether this
is a fortuitous result of testing only a few strains and
how these proliferative differences relate to the pas
genes will be decided when these studies are extended
into the AXB and BXA RI strains.
Possible reasons for differential rates ofcell turnover
are manifold. They may involve regulation of cell pro-
liferative responses (discussed in the next section) or
resultfromdifferentialrates ofcelldeathofneighboring
cell types. Type II and Clara cells divide in response to
the death ofneighboringalveolartype I andbronchiolar
ciliated cells, respectively, to regenerate the wounded
tissue (30,31). How these stem cells recognize that a
neighboring cell has died and how this information is
transduced into a mitogenic signal is unknown. Iftype
I and ciliated cells are genetically programmed to die
(apoptosis) at faster rates in A/J mice than in B6 mice,
this might cause enhanced stem cell replication rates in
A/J lungs.
We have also tested the association ofenhanced pro-
liferation with neoplastic susceptibility bytreatingmice
with noncarcinogenic agents that cause an acute lung
injury followed by regenerative repair. Methylcyclo-
pentadienyl manganese tricarbonyl (MMT) damages
both alveoli and bronchioles, resulting in type II and
Clara cell proliferative peaks 4 days following MMT
administration (30). Weinjected B6micewithMMTand
4 days later with urethane. Tumor multiplicity in-
creased 4-fold (0.4 + 0.2 tumors/mouse, urethane only;
1.6 + 0.4 tumors/mouse, MMT prior to urethane) and
2-fold (0.7 ± 0.3 tumors/mouse, urethane only; 1.4 ±
0.3 tumors/mouse, MMT prior to urethane) in two ex-
periments using 10 mice per group.
Administration of a toxic agent frequently causes an
initial decrease in the number ofdividing cells, presum-
ably because some of these are killed, followed by a
151A. M. MALKINSON
returntothe originallevelofproliferationcharacteristic
of that tissue. When carcinogens are applied to carcin-
ogen-sensitive organs, however, the proliferative re-
bound often exceeds or "overshoots" the original level
before returning to baseline (33). Several carcinogenic
cytotoxic chemotherapeutic agents could be distin-
guished from noncarcinogenic agents on this basis (33).
GRS/A mice sensitive to lung tumorigenesis but not to
liver neoplasia in response to dimethylnitrosamine
(DMN) overshot their normal type II cell Lls following
DMNadministration, butno overshootoccurred intheir
parenchymal liver cells (34). C3Hf/A mice with the op-
posite organ susceptibilities to neoplasia also gave the
opposite proliferative responses. Two studies (27,35) on
alveolartype II cell proliferation in response to urethan
found overshoots in both A/J and B6 mice but at sig-
nificantly different times (12 days following urethan for
A/J versus 24 days for B6) and to different extents (a
2-fold greater degree of proliferation at the peak time
in A/J than in B6 mice). This induced hyperplasia may
be carcinogen specific, however, since other lung car-
cinogens, such as 3-methylcholanthrene, elicited only
slight (35) or negligible (36) type II cell hyperplasia.
The mechanism by which an enhanced cell turnover
rate increases the likelihood ofneoplasia is open to con-
jecture. DNA repair of initiating mutations may not
occur prior to the division ofa rapidly proliferating cell
and the mutation is likelier to be passed along to the
daughter cells; prereplicative repair will more likely
happen in more slowly dividing cells. DNA may also
have increased reactivity toward carcinogens during
replication.
Genetics of Growth Inhibitory
Signals
Neoplastic or unregulated growth can ensue when
cells either overrespond to positive growth signals or
underrespond to negative ones. Unregulated growth
could occur by neoplastic cells producing their own pos-
itive growth factors (37) or by having altered receptors
such that the ability to downregulate receptor concen-
trations in homeostatic response to environmental fluc-
tuations in ligands is lost (38). Resistance to negative
signals could result from inappropriately responding to
a negative growth factor by accelerated rather than
dampened proliferation, as in the case of neoplastic
bronchial cell response to transforming growth factor
(TGF) ,B (39) or by lacking sufficient signal transduction
enzymology to adequately respond to negative factors.
Relative resistance to negative growth factors may un-
derlie the more rapid basal proliferative rates of type
II and Clara cells in A/J versus B6 mice. Iftumor cells
have a decrement in cell signalling effector molecules,
then agenetic propensity toward neoplasia may veer in
this same direction. Susceptible strains might have a
reduced concentration of signalling effector molecules
relative to more resistant strains. We have found nu-
Table 3. Signal transduction in neoplastic
mouse lung epithelial cells.
Effect Reference
Decreased
cAMP pathway
Hormone-stimulated adenylate
cyclase (40)
Gsa GTP binding (41)
Gsa GTPase activity (42)
cAMP-dependent protein
kinase (PKA) type I
isozyme expression (43)
PKA II regulatory subunit
cAMP binding (43)
PKA II autophosphorylation
regulation by cAMP (44,45)
PKA II dissociability by cAMP (46)
Protein kinase C
Activity, concentration,
topology (47)
Glucocorticoid receptor
Glucocorticoid binding (K. A. Droms
and A. M. Malkinson,
unpublished data)
Regulation of growth (K. A. Droms
and A. M. Malkinson,
unpublished data)
Increased
Ca2+-dependent protease
(calpain) activity (45)
merous changes in cell signalling receptors in lung tu-
mors as compared with normal lung tissue and in neo-
plastic cell lines as compared with non-tumorigenic ones
(Table 3) and have begun to make similar comparisons
in A/J and B6 mice.
Glucocorticoids are the most well-studied differentia-
tion factors in lungdevelopment, decreasingtype II cell
proliferation (48) and stimulating the production and
secretion of surfactant (49). Corticosterone (CS), the
majorendogenous rodent glucocorticoid, inhibits regen-
erative recovery from partial pneumectomy in adults
(50). Removing circulating CS by adrenalectomy in-
creased the number of urethan-induced lung tumors in
both A/J and B6 mice, while chronically increasing cir-
culating CS concentrations by pellet implantation low-
ered multiplicities (51). A possible tie-in between glu-
cocorticoids and ras proto-oncogenes is that these
hormones can regulate ras transcription, decreasing K-
ras expression in lymphoma cells (52) and increasing
Ha-ras transcription in keratinocytes (53). Dexameth-
asone (DEX) inhibited the growth of nontumorigenic
C10cells, acelllinederivedfromnormallungepithelium
which had biochemical and morphological features of
type II cells at early passage (54), but not that of neo-
plastic cell lines derived from tumors (K.A. Droms and
A.M. Malkinson, unpublished data). These neoplastic
cells had a diminished ability to bind [3H]DEX and dis-
played mutations in the gene for the glucocorticoid re-
ceptor (55).
We compared the glucocorticoid status ofA1J and B6
mice by examining the number of CS-containing cells
152MOUSE LUNG TUMOR GENETICS
in the adrenal cortices of these strains using an im-
munostaining procedure. B6 mice had cords of CS-con-
taining cells disposed from the cortical periphery to the
medulla, while A/J mice had far fewer CS-containing
cells arranged in no particular pattern (56). When this
traitwasanalyzed amongtheAXB andBXARI strains,
however, no correlation between number of CS-con-
taining adrenocortical cells and lung tumor multiplicity
was observed.
Several studies have indicated that the H-2 locus in
mice affects lung tumor susceptibility. Using congenic
mice which are identical except for different alleles at
the H-2 region, the spontaneous or carcinogen-induced
tumor multiplicities of sensitive mice were lowered
while that of resistant strains increased (57,58). While
these differences are significant, lungtumormultiplicity
in an A/J mouse with a C57BL/10 H-2 locus is still much
higher than in a C57BL/10 mouse which has H-2 alleles
derived from an A/J mouse. This indicates that the H-
2 locus can regulate lung tumor multiplicity, but it is
not the main factor which differentiates sensitive from
resistant strains. H-2 loci contain genes in addition to
the major histocompatibility (MHC) genes which allow
the immune system to discriminate self from nonself.
Among these are genes which govern pulmonary glu-
cocorticoid receptor content (59) and glucocorticoid reg-
ulation of organ development (60).
Wehavefoundanegative correlationbetweenprotein
kinase C (PKC) content and lung epithelial cell prolif-
eration. Treatment of mice with butylated hydroxyto-
luene (BHT), apromoterofmouselungtumors (seenext
section), decreased pulmonary PKC activity (61). Neo-
plastic lung cell lines have less PKC than nontumori-
genic cells, and their ability to translocate PKC from
the cytoplasm to the plasma membrane in response to
phorbol esters is impaired (47). A decreased PKC con-
tent in neoplastic cells and tumors relative to their nor-
mal cohorts has been found in other systems, including
fibroblasts (62) and colon tumors (63). PKC activity de-
creases as cells reach density-dependent inhibition of
growth (K.A. Droms and A.M. Malkinson, unpublished
data) and as lung growth declines during development
(64).
Mouse strains vary in their PKC specific activities.
A/J mice have a 40-60% lower PKC specific activity in
lung, spleen, and brain extracts than do mice from sev-
eral other strains including B6 (65). Lungextracts from
F1 hybrids formed between A/J and BALB/cByJ mice
had PKC activities intermediate tothose ofthe parents,
indicating additive inheritance (65). This genetic activ-
ity difference is mediated by concentration differences
in lung PKC as determined by immunoblotting with
anti-PKC sera(64). IfPKCismeasuredinisolated Clara
cells rather than whole lung extracts, this strain dif-
ference is greatly magnified (Fig. 2), indicating a cell
type-specific regulation of PKC concentration. Studies
are in progress to compare the strain distribution pat-
tern of Clara cell PKC among the AXB and BXA RI
2
FIGURE 2. Westernimmunoblot ofproteinkinase C contentinClara
cells isolated by the procedure described in Walkeret al. (66) from
A/J or B6 mice. Seventy micrograms of protein from a cell ho-
mogenate prepared from six mice of either strain were added to
the appropriate well and blotted with the polyclonal antisera de-
scribed in Weyman et al. (62).
strains with that oflungtumor susceptibilityto test the
functionalsignificance oflowClaracellPKC inA/Jmice.
Genetics of Tumor Modulation by
BHT
Thewidelyused food additive BHT has various pneu-
motoxic effects. Acute exposure causes a reversible
lung damage characterized by extensive alveolar type
I cell necrosis followed by compensatory hyperplasia of
type II cells to regenerate the alveolus (67). All strains
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Table 4. Strain dependence of butylated hydroxytoluene (BHT) effects on mouse lung.
BHT/urethanb Urethan/[BHT]6,
Strain BHT toxicity Prophylaxis Co-carcinogenesis promotionc
A/J + + +
MA/MyJ + 0 0 +
C57BL/6J + + 0
129/J + + +
NGP/N + NDd NDd 0
aToxicity resulting from a single IP injection of 200 mg/kg body weight, as shown by histology or from an increased lung with/body weight
ratio. From Malkinson and Beer (11) and Malkinson (68) and unpublished data..
bAltered tumor multiplicity (+) or lack of it (0) resulting from injecting 200 mg/kg BHT 6 hr prior to a 1 mg/g urethan injection.
cIncreased tumor multiplicity (+) or lack of it (0) resulting from 6 weekly 200 mg/kg injections of BHT following a single 1 mg/kg urethan
injection. From Malkinson and Beer (11) and Thompson et al. (73) and unpublished data.
dNot determined because these mice die from this treatment.
tested exhibit this response (68), although the extent
ofdamage at low BHT concentrations varies with strain
(A.M. Malkinson, unpublished data). BHT itselfis non-
carcinogenic (69) but can modulate the response to a
carcinogen (70,71). A single BHT administration fol-
lowed within a few hours by urethan injection is lethal
to some strains, reduces lungtumormultiplicity in adult
but not neonatal A/J mice, increases multiplicity in B6
and other mice, and has no effect at all on yet other
strains (11,72; A.M. Malkinson, unpublished data).
Lung tumor number is enhanced to various extents in
some strainswhenmiceinjected withurethanarechron-
ically exposed to BHT but not at all in others (11,12,73).
There seems to be no relation between a strain's re-
sponse to one pulmonary effect of BHT versus another
(Table 4). The way that BHT influences the outcome of
carcinogenesis depends on the administration schedule
of BHT and carcinogen and the age and genetic back-
ground of the mouse.
The most well-studied lung tumor modulatory effect
of BHT is that of tumor promotion, whose character-
istics have recently been compared with those of skin
tumor promotion byphorbol esters and livertumorpro-
motion by phenobarbital (74). While most aspects were
similar, the most dramatic difference was that BHT
must be metabolized in order to exert biologic effects
in contrast to the other promotors. This is supported
by several lines of evidence employing agents which
perturb xenobiotic metabolism (68,75) and structural
analogs ofBHT (11,76). BHT metabolism is quite com-
plex and can proceed along either oftwo oxidative path-
ways involving hydroxylation at the tert-butyl position
orring oxidation (77). When the hepatic and pulmonary
metabolism of BHT in mice and rats was compared, a
metabolite hydroxylated at the tert-butyl position,
BHT-OH, was preferentially formed by lung versus
liver and in mouse versus rat (73,77). Mouse strains
most responsive to tumor promotion by BHT also syn-
thesized the most BHT-OH (72). This metabolite was
also 4-fold more potent than BHT at elevating lung tu-
mor multiplicity (73), 20-fold more potent at causing
acute lunginjury (78), and40-fold more potent atkilling
Claracells invitro (A.M. Malkinson, unpublished data).
Thegenesthatregulate sensitivitytothelung-tumor-
promoting effects of BHT are distinct from the pas
genes, as shown by studies with the CXB RI strains
derived from B6 and BALB/cByJ progenitors (11). B6
mice are resistant to urethan, and chronic BHT expo-
sure does not perturb this resistance (11,12). BALB/
cByJ mice develop a few tumors in response to ure-
thane, andthisnumberissignificantlyelevatedbyBHT.
Of the seven CXB RI lines, three respond to urethan
and to BHT like the B6 progenitor and two like the
BALB/cByJ progenitor, but the other two strains have
a unique phenotype. The CXB G and CXB H strains
develop several tumors in response to urethan, and
these multiplicities are unaffected by BHT (11). To ac-
count fortheseunique phenotypes, genes differentfrom
those responsible for susceptibility to urethan carcino-
genesis must exist.
To summarize, the pas genes determine a basal level
of susceptibility to lung tumor growth. Tumor multi-
plicities of sensitive strains can be lowered and those
of resistant strains raised by genetic, hormonal, and
xenobiotic manipulations. These manipulations include
incorporation ofan activated Ha-ras transgene, varying
alleles at the H-2 locus, perturbing circulating corticos-
terone levels, and by administration of BHT. Genes
otherthan thepas genesdetermine theextentand man-
ner by which a strain responds to modulation by BHT.
Some of these genes may operate by regulating the
ability to metabolize BHT along specific pathways.
Pulmonary Adenoma Histogenesis
(pah) Genes
The initial description of a mouse lung tumor by Liv-
ingood in 1896 (79) was that of a papillary adenoma,
which is a benign glandular tumor with fingerlike pro-
jections that compress the adjacent tissue to fonn a
pseudocapsule (Fig. 3). Several studies have described
the structure ofspontaneous tumors (80) and oftumors
at different intervals following carcinogen treatment
(81). A general consensus appears to be that tumor de-
velopment proceeds as a series of stages from hyper-
plasia to a benign and then to a malignant tumor; ma-
lignancy is characterized by structural features such as
nuclear atypia and functional behavior such as invasion
into adjacent tissue and metastasis (82). Most studies
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.a
FIGURE 3. Alveolar (upper panel) and papillary (lower panel) arrangements of cells within urethan-induced lung tumors in A/J mice. From
Thaete et al. (83).
onlungtumorstructure used sensitive A/J miceinorder
to have large tumor numbers for study. Most benign
tumors were of an alveolar or solid tumor pattern in
which cells are compactly arranged with nocompression
ofnearby alveoli (Fig. 3). Papillary tumors are also seen
in A/J mice, and the relative proportion of these two
histological formsoftumorsappears tochange withtime
after carcinogen treatment. At later times, more ofthe
benign tumors are ofthe papillary type (83). When this
alveolar:papillary ratio is determined as a function of
tumor size, a greater fraction of the larger tumors are
papillary rather than alveolar (83). It is the papillary
rather than the alveolar arrangement that is found
within malignant tumors (83,84). Because papillary tu-
mors appear later than alveolar and are physically jux-
taposed nearadenocarcinomas morefrequentlythan are
alveolar tumors, it was proposed (83) that malignant
tumors arise predominantly from the papillary tumors.
Ifa single time period following carcinogen treatment
is selected for examining benign tumor histology,
strains were found to vary in the proportion ofalveolar
and papillary tumors. Of the inbred strains we have
studied, that with the highest proportion of alveolar
tumors 14 to 16 weeks following urethan administration
is A/J and that with the lowest proportion is MA/MyJ.
When (MA/MyJ x A/J) hybrid mice were examined,
theywere ofthe MA/MyJphenotype (A/J, 84%alveolar;
MA, 34%; [MA x A]F1, 38%), suggesting that the al-
lele(s) prescribing a papillary phenotype was dominant
(84). The poor breeding activity of MAIMyJ mice and
the recent Morrell Park fire at Jackson Laboratories
have temporarily suspended our efforts to further ex-
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amine this aspect of genes which regulate benign lung
tumor phenotype.
We have also evaluated the alveolar:papillary tumor
status ofthe AXB and BXA RI strains (85). While the
phenotypes ofthe A/J and B6 progenitors were similar
to each other in being 84% and 75% alveolar, respec-
tively, the RI strains ranged from 0 to 100% alveolar.
This divergence of RI strain phenotype from those of
their progenitors indicates that multiple genes regulate
this trait, which we refer to as pulmonary adenoma
histogenesis or pah genes. When the percentage of al-
veolar tumors in each RI strain was compared to their
respectivetumormultiplicities, nocorrelationwasseen,
indicating that the pas and pah genes are distinct.
The biological significance ofthepah genes relates to
the association between papillary tumors and the de-
velopment of malignancy; since these genes determine
the histologic pattern, they also regulate the likelihood
of tumor progression. We must therefore inquire into
the origin of these histologic patterns among the ad-
enomas: two views oftheir histogenesis currently exist
(Fig. 4).
Light microscopic examination ofserial lung sections
revealed that the location of most tumors was in the
alveoli and not in the bronchi or bronchioles (86). Ul-
trastructural studies showed the presence of lamellar
bodies which are characteristic of the surfactant-se-
creting, alveolartype II cells (87). Type II cellsundergo
compensatory hyperplasia when neighboring type I
cells are damaged by various pneumotoxins (30). Type
II cells have a high content of the cytochrome P-450
enzymes necessary for metabolic activation of proxi-
mate carcinogens (88) and are the cell oforigin of some
human bronchiolo-alveolar carcinomas (BAC) (20). Fur-
ther, some mouse lung adenomas secrete surfactant
apoproteins (88). It is therefore reasonable to conclude
that mouse lung adenomas arise from alveolar type II
cells (90). Since the papillary adenomas have a longer
latency than the alveolar adenomas (83,91), a single
pathwaymodelistenable inwhichpapillarytumors rep-
resent a more advanced stage ofbenign tumor growth
than alveolar tumors. Both tumor types would arise
Models of Lung Tumor Histogenesis
Singlepathwaymodel
Alveolar Type 11 Cell
or _ Hyperplasia _ Alveolar _ PApilrya Cancer
Fetal Alveolar Adenoma Adenoma
Type 11
Precursor Cell
Dualpathwaymodel
Alveolar Type 11 Cell
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Parenchymal - Hyperplasia Adenoma
Epithelial
Precursor Cell
Clara Cell
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Parenchymal Hyperplasia -4t P a Cancer
Epithelial
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FIGURE 4. Different models ofthe time-dependent development of
adenocarcinoma in mouse lung.
from hyperplasia of mature type II cells or from nests
of cells which are the postulated developmental pre-
cursor cell to the type II cell.
There is, however, another point of view of the cel-
lular origin ofthese tumors. The likelihood that at least
some of the adenomas, particularly the alveolar aden-
omas, arise from mature or immature type II cells
seems incontrovertible. Papillary tumors, however,
may arise from hyperplasia ofmature bronchiolar Clara
cells or of a precursor of this cell type. Kauffman and
co-workers (92) found that the ultrastructure of papil-
lary tumors resembles that of Clara cells, rather than
type II cells, in havingpleimorphic nuclei, considerable
numbers oflarge mitochondria, few ifany lamellar bod-
ies, and abundant smooth endoplasmic reticulum. Clara
cells can act as the bronchiolar stem cell and proliferate
and then differentiate into ciliated cells when these lat-
ter fragile cells are damaged (32). Clara cells have the
highest content of cytochrome P-450 enzymes of any
cell in the lung (93) and are a major cell origin of BAC
in man and other species (20,94,95). Clara cells also
synthesize surfactant apoproteins (96). Some radiola-
beled carcinogens were preferentially taken up by
mouse Clara cells (97) and initial hyperplastic foci in-
duced by some carcinogens are bronchiolar in origin
(97). Mouse Clara cells and papillary tumors both have
high amounts of succinate dehydrogenase activity,
while that oftype II and alveolar tumors is much lower
(85). Since it is otherwise difficult to explain why pap-
illary tumors have so many Clara-like features en route
to malignancy, these Clara-like characteristics support
the dual pathway model of adenoma histogenesis illus-
trated in Figure 4.
Theimportanceofunambiguouslyunderstandingpap-
illary cellorigin is important forunderstandingthe pro-
gression of this tumor system. Either the pah genes
determinewhichcelltypeundergoes aninitiatingevent,
or they determine whether an alveolar adenoma will
progress to the papillary stage and thus have increased
probability ofbecoming malignant.
I thank D.G. Beer, K.A. Droms, K. Moriwaki, and L.G. Thaete
for allowing me to present their unpublished data, and K.A. Droms
and L.G. Thaete for their help in preparing this manuscript. This
work was funded by U.S. PHS grants ES02370, CA33497 and Re-
search Career Development Award CA00939.
REFERENCES
1. Strong, L. C. Inbred mice in science. In: Origins of Inbred Mice
(H.C. Morse, III, Ed.), Academic Press, New York, 1978, pp.
45-68.
2. Murphy, J. B., and Sturm, E. Primary lung tumors in mice fol-
lowing cutaneous application of coal tar. J. Exp. Med. 42: 693-
700 (1925).
3. Andervont, H. B. Pulmonary tumors in mice. V. Further studies
on the influence of heredity upon spontaneous and induced lung
tumors. Pub. Health Rep. 53: 135-145 (1938).
4. Heston, W. E. Genetic analysis of susceptibility to induced pul-
monary tumors in mice. J. Natl. Cancer Inst. 3: 69-78 (1942).
5. Malkinson, A. M. The genetic basis of susceptibility to lung tu-
mors in mice. Toxicology 54: 241-271 (1989).
6. Demant, P., Oomen, L. C. J. M., and Oudshoorn-Snoek, M. Ge-MOUSE LUNG TUMOR GENETICS 157
netics of tumor susceptibility in the mouse: MHC and non-MHC
genes. Adv. Cancer Res. 53: 117-180 (1989).
7. Witschi, H. P. Enhancement of tumor formation in mouse lung
by dietary butylated hydroxytoluene. Toxicology 21: 95-104
(1981).
8. Bailey, D. W. Recombinant-inbred strains, an aid to findingiden-
tity, linkage and function of histocompatibility and other genes.
Transplantation 11: 325-327 (1971).
9. Malkinson, A. M., Nesbitt, M. N., andSkamene, E. Susceptibility
to urethan-induced pulmonary adenomas between A/J and
C57BL/6J mice: use of AXB and BXA recombinant inbred lines
indicating a three-locus genetic model. J. Natl. Cancer Inst. 7:
971-974 (1985).
10. Malkinson, A. M., Nesbitt, M. N., and Skamene, E. Analysis of
lung tumor susceptibility differences using the AXB and BXA
recombinant inbred strains of mice. In: Genetic Control of Host
Resistance to Infection and Malignancy (E. Skamene Ed.), Alan
R. Liss, New York, 1985, pp. 805-810.
11. Malkinson, A. M., and Beer, D. S. Pharmacologic and genetic
studies on the modulatory effects ofbutylated hydroxytoluene on
mouse lung adenoma formation. J. Natl. Cancer Inst. 73: 925-
933 (1984).
12. Malkinson, A. M., and Beer, D. S. Major effect on susceptibility
to urethan-induced pulmonary adenoma by a single gene in
BALB/cBy mice. J. Natl. Cancer Inst. 70: 931-936 (1983).
13. Bloom, J. L. and Falconer, D. S. A gene with major effect on
susceptibility to induced lung tumors in mice. J. Natl. Cancer
Inst. 33: 607-618 (1964).
14. Nesbitt, M. N., and Skamene, E. Recombinant inbred mouse
strains derived from A/J and C57BL/6J: a tool for the study of
genetic mechanisms in host resistance to infection and malig-
nancy. J. Leukocyte Biol. 36: 357-364 (1984).
15. Ryan, J., Barker, P. E., Nesbitt, M. N., and Ruddle, F. H.
KRAS2 asageneticmarkerforlungtumorsusceptibilityininbred
mice. J. Natl. Cancer Inst. 79: 1351-1357 (1987).
16. You, M., Candrian, J., Maronpot, R. R., Stoner, G. D., and
Anderson, M. W. Activation ofthe Ki-ras protooncogene in spon-
taneously occurring and chemically-induced lung tumors of the
strain A mouse. Proc. Natl. Acad. Sci. U.S.A. 86: 3070-3074
(1989).
17. Sandgren, E. P., Quaife, C. J., Pinkert, C. A., Palmiter, R. D.,
and Brinster, R. C. Oncogene-induced liver neoplasia in trans-
genic mice. Oncogene 4: 715-724 (1989).
18. Sinn, E., Mullen, W., Pattengale, P., Tepler, I., Wallace, R.,
and Leder, P. Coexpression of MMTV/v-Ha-ras and MMTV/c-
myc genes in transgenic mice: synergistic action ofoncogenes in
vivo. Cell 49: 465-475 (1987).
19. Suda, Y., Aizuma, S., Hirai, S. I., Inoue, T., Furuta, Y., Suzuki,
M., Hirohashi, S., and Ikawa, Y. Driven bythe same Igenhancer
and SV40T promoter ras induced lungadenomatous tumors, myc
induced pre-B cell lymphomas and SV40 large T gene, a variety
of tumors in transgenic mice. EMBO J. 6: 4055-4065 (1987).
20. Gazdar, A. F., and Linnoila, R. I. The pathology oflung cancer-
changing concepts and newer diagnostic techniques. Sem. Oncol.
55: 215-225 (1988).
21. Joishy, S. K., Cooper, R. A., and Rowley, P. T. Alveolar cell
carcinoma in identical twins. Similarity in time of onset, histo-
chemistry, and site ofmetastasis. Ann. Intern. Med. 87: 447-450
(1977).
22. Bos, J. L. Ras oncogenes in human cancer: areview. Cancer Res.
49: 4682-4689 (1989).
23. Deschner, E. E., Long, F. C., Hakissian, M., and Herrman, S.
L. Differential susceptibility of AKR, C57BL/6J and CFI mice
to 1,2-dimethylhydrazine-induced colonic tumor formation pre-
dicted by proliferative characteristics of colonic epithelial cells.
J. Natl. Cancer Inst. 70: 279-282 (1983).
24. Inui, T., Tsubara, A., and Morii, S. Incidence of precancerous
foci ofmammary glands and growth rate oftransplantable mam-
mary cancersinsialoadrenalectomized mice. J. Natl. Cancer Inst.
81: 1660-1663 (1989).
25. Solt, D. B., Medline, A., and Farber, E. Rapid emergence of
carcinogen-induced hyperplastic lesions in a new model for the
sequential analysis oflivercarcinogenesis. Am.J. Pathol. 88:595-
618 (1977).
26. Rous, P., and Kidd, J. G. Conditional neoplasia and subthreshold
neoplastic states. J. Exp. Med. 73: 365-390 (1941).
27. Thaete, L. G., Beer, D. G., and Malkinson, A. M. Genetic vari-
ation in the proliferation ofmurine pulmonary type II cells: basal
rates and alterations following urethan treatment. Cancer Res.
46: 5335-5338 (1986).
28. Thaete, L. G., Ahnen, D. J., and Malkinson, A. M. Proliferating
cell nuclear antigen (PCNA/cyclin) immunocytochemistry as a
labelling index in mouse lung tissues. Cell Tissue Res. 256: 167-
173 (1989).
29. Prelich, G., Tan, C. -K., Kostura, M., Matthews, M. B., So, A.
G., Downey, K. M., and Stillman, B. Functional identity of pro-
liferating cell nuclear antigen and a DNA polymerase-delta aux-
iliary protein. Nature 326: 517-520 (1987).
30. Adamson, I. Y. R., and Bowden, D. H. The type 2 cell as pro-
genitor of alveolar epithelial regeneration. A cytodynamic study
in mice after exposure to oxygen. Lab. Invest. 20: 35-42 (1974).
31. Evans, M. J., Johnson, L. V., Stephens, R. J., and Freeman, G.
Renewal ofthe terminal bronchiolar epithelium in the rat follow-
ing exposure to NO2 or 03. Lab.Invest. 35: 246-257 (1976).
32. Hakkinen, P. J., and Haschek, W. M. Pulmonarytoxicity ofmeth-
ylcyclopentadienyl manganese tricarbonyl: nonciliated bronchio-
lar epithelial (Clara) and alveolar damage in the mouse, rat and
hamster. Toxicol. Appl. Pharmacol. 65: 11-22 (1982).
33. Wheeler, G. P., and Alexander, J. A. Rate of DNA synthesis as
an indication ofdrugtoxicity and as aguide for scheduling cancer
therapy. Cancer Treat. Rep. 62: 755-769 (1978).
34. De Munter, H. K., Den Engelse, L., and Emmelot, P. Studies
on lung tumors IV. Correlation between [3H]thymidine labeling
of lung and liver cells and tumor formation in GRS/A and C3Hf/
A male mice following administration of dimethylnitrosamine.
Chem.-Biol. Interact. 24: 299-316 (1979).
35. Shimkin, M. B., Sasaki, T., McDonough, M., Baserga, R.,
Thatcher, D., and Weider, R. Relation of thymidine index to
pulmonary tumor response in mice receiving urethan and other
carcinogens. Cancer Res. 29: 994-998 (1969).
36. Witschi, H. P., and Morse, C. C. Cell kinetics in mouse lung
following administration of carcinogens and butylated hydroxy-
toluene. Toxicol. Appl. Pharmacol. 78: 464-472 (1985).
37. Delarco, J., and Todaro, G. J. Growth factors from murine sar-
coma virus-transformed cells. Proc. Natl. Acad. Sci. U.S.A. 75:
4001-4005 (1978).
38. Terzaghi-Howe, M. Changes in response to, and production of,
transforming growth factors type P duringneoplastic progression
in cultured rat tracheal epithelial cells. Carcinogenesis 10: 973-
980 (1989).
39. Jetten, A. M., Shirley, J. E., and Stoner, G. D. Regulation of
proliferation and differentiation of respiratory tract-epithelial
cells by TGF-beta. Exp. Cell Res. 166: 539-549 (1986).
40. Droms, K. A., Haley, B. E., Smith, G. J., and Malkinson, A. M.
Decreased 8N3-[y-32P]-GTP photolabeling ofGSa in tumorigenic
lung epithelial cell lines: association with decreased hormone re-
sponsiveness and loss ofcontact-inhibited growth. Exp. Cell Res.
182: 330-339 (1989).
41. Droms, K. A., Haley, B. E., and Malkinson, A. M. Decreased
incorporation ofthe photoaffinity probe 8N3(_y-32P)-GTP into a 45
KD protein in lung tumors. Biochem. Biophys. Res. Commun.
144: 591-597 (1987).
42. Droms, K. A., Haley, B. E., and Malkinson, A. M. Mechanisms
of decreased beta-adrenergic stimulation of adenylate cyclase in
neoplastic mouse lung epithelial cell lines. FASEB J. 4: A1137
(1990).
43. Lange-Carter, C. A., Fossli, T., Jahnsen, T., and Malkinson, A.
M. Decreased expression of the type I isozyme of cAMP-depen-
dent protein kinase in tumor cell lines oflung epithelial origin. J.
Biol. Chem. 265: 7814-7818 (1990).
44. Malkinson, A. M., and Butley, M. S. Alterations in cyclic AMP-
dependent protein kinases during normal and neoplastic lung de-
velopment. Cancer Res. 41: 1334-1341 (1981).
45. Butley, M. S., Beer, D. G., and Malkinson, A. M. Functional
changes in the regulatory subunit (RII) of the type II cAMP-158 A. M. MALKINSON
dependent protein kinase during normal and neoplastic lung de-
velopment. Cancer Res. 44: 2689-2697 (1984).
46. Butley, M. S., Stoner, G. D., Beer, D. G., Beer, D. S., Mason,
R. J., and Malkinson, A. M. Changes in cyclic AMP-dependent
protein kinases during the progression ofurethan-induced mouse
lung tumors. Cancer Res. 45: 3677-3685 (1985).
47. Nicks, K. M., Droms, K. A., Fossli, T., and Malkinson, A. M.
Altered functions ofprotein kinase C and cyclic AMP-dependent
protein kinase in a cell line derived from a mouse lung tumor.
Cancer Res. 49: 5191-5198 (1989).
48. Kauffman, S. L. Proliferation, growth, and differentiation ofpul-
monary epithelium in fetal mouse lung exposed transplacentally
to dexamethasone. Lab. Invest. 37: 497-501 (1977).
49. Kotas, R. V., and Avery, M. E. Accelerated appearance of pul-
monary surfactant in the fetal rabbit. J. Appl. Physiol. 30: 358-
361 (1971).
50. Bennett, R. A., Colony, D. C., Addison, J. C,. and Rannels, D.
E. Effects of prior adrenalectomy on postpneumonectomy lung
growth in the rat. Am. J. Physiol. 248: E70-E74 (1985).
51. Droms, K. A., Fernandez, C. A., Thaete, L. G., and Malkinson,
A. M. Effects ofadrenalectomy and corticosterone administration
on mouse lung tumor susceptibility and histogenesis. J. Natl.
Cancer Inst. 80: 365-369 (1988).
52. Eastman-Reks, S. B., and Vedeckis, W. V. Glucocorticoid inhi-
bition of c-myc, c-myb, and c-Ki-ras expression in a mouse lym-
phoma cell lines. Cancer Res. 46: 2457-2462 (1986).
53. Strawhecker, J. M., Betz, N. A., Neades, R. Y., Houser, W.,
and Pelling, J. C. Binding ofthe 97 kDA glucocorticoid receptor
to the 5'-upstream flanking region of the mouse c-Ha-ras onco-
gene. Oncogene 4: 1317-1322 (1989).
54. Smith, G. J., Lemesurier, S. M., De Montfort, M. C., and Lykke,
A. W. J. Development and characterization oftype2pneumocyte-
related cell lines from normal adult mouse lung. Pathology 16:
401-405 (1984).
55. Nuzum, E., Howell, A., Droms, K., Malkinson, A. M., and Beer,
D. Structure and expression of the glucocorticoid receptor gene
in urethan-induced lung tumors. Proc. Am. Assoc. Cancer Res.
30: 1223 (1989).
56. Thaete, L. G., Nesbitt, M. N., and Malkinson, A. M. Genetic
analysis of the distribution of corticosterone-containing cells in
the mouse adrenal cortex. Proc. Soc. Exp. Biol. Med. 194: 97-
102 (1990).
57. Faraldo, M. J., Dux, A., Muhlbock, O., and Hart, G. Histocom-
patibility genes (the H-2 complex) and susceptibility to sponta-
neous lung tumors in mice. Immunogenetics 9: 383-404 (1979).
58. Miyashita, N., and Moriwaki, K. H-2-controlled genetic suscep-
tibility to pulmonary adenomas induced by urethane and 4-nitro-
quinoline 1-oxide in A/Wy congenic strains. Jpn. J. Cancer Res.
78: 494-498 (1987).
59. Goldman, A. S,, and Katsumata, M. Murine glucocorticoid re-
ceptors: new evidence for a discrete receptor influenced by H-2.
Arch. Biochem. Biophys. 249: 316-325 (1986).
60. Demant, P., Corticosteroid-induced cleft palate: cis interaction of
MHC genes and hybrid resistance. Immunogenetics 22: 183-188
(1985).
61. Malkinson, A. M., Beer, D. S., Sadler, A. J., and Coffman, D.
S. A decrease in the protein kinase C-catalyzed phosphorylation
of an endogenous 36K lung protein following treatment of mice
with the tumor modulatory agent, butylated hydroxytoluene.
Cancer Res. 45: 5751-5756 (1985).
62. Weyman, C. M., Taparowsky, E. J., Wolfson, M., and Ashendel,
C. C. Partial down-regulation of protein kinase C in C3H/1OT'/2
mouse fibroblasts transfected with the human Ha-ras oncogene.
Cancer Res. 48: 6535-6541 (1988).
63. Guillem, J. G., O'Brian, C. A., Fitzer, C. J., Fonde, K. A.,
LoGerfo, P., Treat, M., and Weinstein, I. B. Altered levels of
protein kinase C and Ca"+-dependent protein kinases in human
colon carcinomas. Cancer Res. 47: 2036-2039 (1987).
64. Malkinson, A. M., Girard, P. R., and Kuo, J. F. Strain-specific
postnatalchangesintheactivityandtissuelevelsofproteinkinase
C. Biochem. Biophys. Res. Commun. 145: 733-739 (1987).
65. Malkinson, A. M., Conway, K., Bartlett, S., Butley, M. S., and
Conroy, C. Straindifferences amonginbredmiceinproteinkinase
Cactivity. Biochem. Biophys. Res. Commun. 122:492-498(1984).
66. Walker, S. R., Hale, S., Malkinson, A. M., and Mason, R. J.
Properties of isolated nonciliated bronchiolar cells from mouse
lung. Exp. Lung Res. 15: 553-573 (1989).
67. Adamson, I. Y., Bowden, D. H., Cote, M. G., and Witschi, H.
P. Lung injury bybutylated hydroxytoluene. Lab Invest. 36: 26-
32 (1977).
68. Malkinson, A. M. Prevention of BHT-induced lung damage in
mice by cedar terpene administration. Toxicol. Appl. Pharmacol.
49: 551-560 (1979).
69. Shirai, T., Hagiwara, A., Kurata, Y., Shibata, M., Fukushima,
S., and Ito, N. Lack of carcinogenicity of butylated hydroxyto-
luene on long-term administration to B6C3F1 mice. Fd. Chem.
Toxicol. 20: 861-865 (1982).
70. Malkinson, A. M. Reviews on putative mutagens and carcinogens
in foods. III. Butylated hydroxytoluene (BHT). Environ. Muta-
gen. 5: 353-362 (1983).
71. Malkinson, A. M. Multiple modulatory effects of butylated hy-
droxytoluene ontumorigenesis. Cancer Invest. 3:209-211 (1985).
72. Malkinson, A. M., and Thaete, L. G. Effects ofstrain and age on
prophylaxis and co-carcinogenesis ofurethan-induced mouse lung
adenomas by butylated hydroxytoluene. Cancer Res. 46: 1694-
1967 (1986).
73. Thompson, J. A., Schullek, K. M., Fernandez, C. A., and Malk-
inson, A. M. A metabolite of butylated hydroxytoluene with po-
tent tumor promoting activity in mouse lung. Carcinogenesis 10:
773-775 (1989).
74. Witschi, H., Malkinson, A. M., and Thompson, J. A. Metabolism
andpulmonarytoxicityofbutylatedhydroxytoluene(BHT). Phar-
macol. Ther. 42: 89-113 (1989).
75. Kehrer, J. P., and Witschi, H. P. Effects of drug metabolism
inhibitors on butylated hydroxytoluene induced pulmonary tox-
icity in mice. Toxicol. Appl. Pharmacol. 53: 333-342 (1980).
76. Mizutani, T., Yamamoto, K., and Tajima, K. Isotope effects on
the metabolism and pulmonary toxicity of butylated hydroxyto-
luene inmice bydeuteration ofthe4-methyl group. Toxicol. Appl.
Pharmacol. 69: 283-290 (1983).
77. Thompson, J. A., Malkinson, A. M., Wand, M. D., Mastovich, S.
L., Mead, E. W., Schullek, K. M., and Laudenschlager, W. G.
Oxidative metabolism ofbutylated hydroxytoluenebyhepaticand
pulmonary microsomes from rats and mice. Drug Metab. Disp.
15: 883-840 (1987).
78. Malkinson, A. M., Thaete, L. G., Blumenthal, E. J., and Thomp-
son, J. A. Evidence for an obligatory role of tert-butyl hydrox-
ylation on the induction of pneumotoxicity in mice by butylated
hydroxytoluene (BHT). Toxicol. Appl. Pharmacol. 101: 196-204
(1989).
79. Livingood, L. E. Tumors in the mouse. Johns Hopkins Bull. 66/
67: 177-179 (1896).
80. Kimura, I. Progression ofpulmonarytumorsinmice. I. Histologic
studies ofprimary and transplanted pulmonary tumors. Acta Pa-
thol. Jpn. 21: 13-56 (1971).
81. Shimkin, M. B., and Polissar, M. J. Some quantitative observa-
tions on the induction and growth of primary pulmonary tumors
in strain A mice receiving urethan. J. Natl. Cancer Inst. 16: 75-
96 (1955).
82. Stewart, H. L., Dunn, T. B., Snell, K. C., and Deringer, M. K.
Tumours of the respiratory tract. In: Pathology of Tumours in
Laboratory Animals (V.S. Turosov, Ed.), International Agency
for Research on Cancer, Lyon, 1979, pp. 251-288.
83. Thaete, L. G., Gunning, W. T., Stoner, G. D., and Malkinson,
A. M. Cellularderivation oflungtumors insensitiveandresistant
strains of mice: results at twenty-eight and fifty-six weeks after
urethan treatment. J. Natl. Cancer Inst. 78: 743-749 (1987).
84. Beer, D. G., and Malkinson, A. M. Localization of specific [3H]-
dexamethasone binding in urethane-induced mouse lung tumors.
Cancer Res. 44: 3546-3553 (1984).
85. Thaete, L. G., Nesbitt, M. N., and Malkinson, A. M. Regulation
of mouse lung tumor development by pulmonary adenoma his-
togenesis genes. Proc. Am. Assoc. Cancer Res. 31: 38 (1990).
86. Grady, H. G., and Stewart, H. L. Histogenesis of induced pul-MOUSE LUNG TUMOR GENETICS 159
monary tumors in strain A mice. Am. J. Pathol. 16: 417-432
(1940).
87. Svoboda, D. J. Ultrastructure ofpulmonary tumors inmice. Can-
cer Res. 22: 1197-1201 (1962).
88. Devereux, T. R., and Fouts, J. R. Isolation of pulmonary cells
and use in studies of xenobiotic metabolism. Methods Enzymol.
77: 147-154 (1981).
89. Singh, G., Katyal, S. L., and Torikata, C. Carcinoma oftype II
pneumocytes. Immunodiagnoses of a subtype of bronchiolo-al-
veolar carcinomas. Am. J. Pathol. 102: 195-208 (1983).
90. Rehm, S., Ward, J. M., Ten Have-Opbroek, A. A. W., Anderson,
L. M., Singh, G., Katyal, S. L., and Rice, J. M. Mouse papillary
lung tumors transplacentally induced by N-nitrosoethylurea: evi-
dence for alveolar type II cell origin by comparative light micro-
scopic, ultrastructural, and immunohistochemical studies. Cancer
Res. 48: 148-160 (1988).
91. Kauffman, S. L. Histogenesis ofthepapillary Claracelladenoma.
Am. J. Pathol. 103: 174-180 (1981).
92. Kauffman, S. L., Alexander, L., and Sass, L. Histologic and
ultrastructural features ofthe Clara cell adenoma ofmouse lung.
Lab Invest. 40: 708-716 (1979).
93. Boyd, M. R., Statham, C. N., and Longo, N. S. The pulmonary
Clara cell as a target for toxic chemicals requiring metabolic ac-
tivation; studies with carbon tetrachloride. J. Pharmacol. Exp.
Ther. 212: 109-114 (1980).
94. Greenberg, S. D., Smith, M. N., and Spjut, H. J. Bronchiolo-
alveolar carcinoma: cell of origin. Am. J. Clin. Pathol. 63: 153-
167 (1975).
95. Kennedy, A. R., McGandy, R. B., and Little,J. B. Histochemical,
light and electron microscopic study ofPolonium-210 induced pe-
ripheral tumors in hamster lung: evidence implicating the Clara
cell as the cell of origin. Eur. J. Cancer 13: 1325-1340 (1977).
96. Walker, S. R., Williams, M. C., and Benson, B. Immunocyto-
chemical localization ofthe major surfactant apoproteins in type
II cells, Clara cells and alveolar macrophages ofrat lung. J. His-
tochem. Cytochem. 34: 1137-1148 (1986).
97. Kanisawa, M. Developmental steps of experimentally induced
adenocarcinoma ofthe lung. In: Morphogenesis of Lung Cancer,
Vol. 1 (Y. Shimosato, M.R. Melamed, and P. Nettesheim, Eds.),
CRC Press, Boca Raton, FL, 1982, pp. 181-204.